Skip to content

Trial · Interventional

CompletedPhase 1Results postedRegistry data

A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight

NCTNCT06440980 (opens ClinicalTrials.gov in a new tab)Other id18617Other idJ2A-MC-GZPI
Open at ClinicalTrials.govAsk about this trial

Overview

Status
Completed
Phase
Phase 1
Enrollment
533 participants (actual)
Sponsor
Eli Lilly and Company · Industry
Design
Randomized · Open label (no masking)
Countries
1 country

United States

Start
24 Jun 2024
Primary completion
2 Jun 2025
Completion
2 Jun 2025
First posted
4 Jun 2024
Last update posted
17 Jul 2026
Conditions
Healthy · Obese · Overweight · Obesity

Timeline

1 trial · 1 completed · 1 with posted results

  • Completed
  • Ongoing
  • Not yet recruiting
  • Stopped
  • Estimated dates (est.)
  • Results posted
202420252026
  1. Ph 1

    A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight

    NCT06440980

    24 Jun 2024 to 2 Jun 2025

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

The main purpose of this study is to see how much of orforglipron (study drug) gets into the bloodstream and how long it takes the body to get rid of it when given as capsules compared to tablets in healthy overweight and obese participants. The safety and tolerability (side effects) of orforglipron when given as capsules and tablets will also be evaluated. The study will be conducted in two parts, with part A and B lasting up to approximately 25 and 22 weeks each respectively, including the screening period.

Interventions

  • OrforglipronDrug

Arms14

  • Experimental

    Part A: LY3502970 QD Oral Administration (Cohort 1A, Sequence 1)

    Participants received LY3502970 orally once daily (QD) across inpatient Treatment Periods 1-12 (7 days per period), followed by a follow-up visit approximately 7 days after the last dose. Doses were administered as follows: * Period 1: 1 mg (Capsule) * Period 2: Dose Level 2 (Tablet) * Period 3: Dose Level 1 (Tablet) * Period 4: Dose Level 3 (Tablet) * Period 5: 3 mg (Capsule) * Period 6: Dose Level 5 (Tablet) * Period 7: Dose Level 4 (Tablet) * Period 8: Dose Level 6 (Tablet) * Period 9: 6 mg (Capsule) * Period 10: Dose Level 8 (Tablet) * Period 11: Dose Level 7 (Tablet) * Period 12: Dose Level 9 (Tablet)

  • Experimental

    Part A: LY3502970 Oral Administration (Cohort 1A, Sequence 2)

    Participants received LY3502970 orally QD across inpatient Treatment Periods 1-12 (7 days per period), followed by a follow-up visit approximately 7 days after the last dose. Doses were administered as follows: * Period 1: Dose Level 2 (Tablet) * Period 2: 1 mg (Capsule) * Period 3: Dose Level 3 (Tablet) * Period 4: Dose Level 1 (Tablet) * Period 5: Dose Level 5 (Tablet) * Period 6: 3 mg (Capsule) * Period 7: Dose Level 6 (Tablet) * Period 8: Dose Level 4 (Tablet) * Period 9: Dose Level 8 (Tablet) * Period 10: 6 mg (Capsule) * Period 11: Dose Level 9 (Tablet) * Period 12: Dose Level 7 (Tablet)

  • Experimental

    Part A: LY3502970 Oral Administration (Cohort 1A, Sequence 3)

    Participants received LY3502970 orally QD across inpatient Treatment Periods 1-12 (7 days per period), followed by a follow-up visit approximately 7 days after the last dose. Doses were administered as follows: * Period 1: Dose Level 1 (Tablet) * Period 2: Dose Level 3 (Tablet) * Period 3: 1 mg (Capsule) * Period 4: Dose Level 2 (Tablet) * Period 5: Dose Level 4 (Tablet) * Period 6: Dose Level 6 (Tablet) * Period 7: 3 mg (Capsule) * Period 8: Dose Level 5 (Tablet) * Period 9: Dose Level 7 (Tablet) * Period 10: Dose Level 9 (Tablet) * Period 11: 6 mg (Capsule) * Period 12: Dose Level 8 (Tablet)

  • Experimental

    Part A: LY3502970 Oral Administration (Cohort 1A, Sequence 4)

    Participants received LY3502970 orally QD across inpatient Treatment Periods 1-12 (7 days per period), followed by a follow-up visit approximately 7 days after the last dose. Doses were administered as follows: * Period 1: Dose Level 3 (Tablet) * Period 2: Dose Level 1 (Tablet) * Period 3: Dose Level 2 (Tablet) * Period 4: 1 mg (Capsule) * Period 5: Dose Level 6 (Tablet) * Period 6: Dose Level 4 (Tablet) * Period 7: Dose Level 5 (Tablet) * Period 8: 3 mg (Capsule) * Period 9: Dose Level 9 (Tablet) * Period 10: Dose Level 7 (Tablet) * Period 11: Dose Level 8 (Tablet) * Period 12: 6 mg (Capsule)

  • Experimental

    Part A: LY3502970 Oral Administration (Cohort 2A, Sequence 1)

    Participants received LY3502970 orally QD during home dosing Treatment Periods 1-6 (1 mg, 3 mg and 6 mg; Capsule), followed by inpatient Treatment Periods 7-18 (7 days per period) and a follow-up visit approximately 7 days after the last dose. Doses during inpatient periods were administered as follows: * Period 7: 12 mg (Capsule) * Period 8: Dose Level 11 (Tablet) * Period 9: Dose Level 10 (Tablet) * Period 10: Dose Level 12 (Tablet) * Period 11: 24 mg (Capsule) * Period 12: Dose Level 14 (Tablet) * Period 13: Dose Level 13 (Tablet) * Period 14: Dose Level 16 (Tablet) * Period 15: 36 mg (Capsule) * Period 16: Dose Level 17 (Tablet) * Period 17: Dose Level 15 (Tablet) * Period 18: Dose Level 18 (Tablet)

  • Experimental

    Part A: LY3502970 Oral Administration (Cohort 2A, Sequence 2)

    Participants received LY3502970 orally QD during home dosing Treatment Periods 1-6 (1 mg, 3 mg, and 6 mg; Capsule), followed by inpatient Treatment Periods 7-18 (7 days per period) and a follow-up visit approximately 7 days after the last dose. Doses during inpatient periods were administered as follows: * Period 7: Dose Level 11 (Tablet) * Period 8: 12 mg (Capsule) * Period 9: Dose Level 12 (Tablet) * Period 10: Dose Level 10 (Tablet) * Period 11: Dose Level 14 (Tablet) * Period 12: 24 mg (Capsule) * Period 13: Dose Level 16 (Tablet) * Period 14: Dose Level 13 (Tablet) * Period 15: Dose Level 17 (Tablet) * Period 16: 36 mg (Capsule) * Period 17: Dose Level 18 (Tablet) * Period 18: Dose Level 15 (Tablet)

  • Experimental

    Part A: LY3502970 Oral Administration (Cohort 2A, Sequence 3)

    Participants received LY3502970 orally QD during home dosing Treatment Periods 1-6 (1 mg, 3 mg and 6 mg; Capsule), followed by inpatient Treatment Periods 7-18 (7 days per period) and a follow-up visit approximately 7 days after the last dose. Doses during inpatient periods were administered as follows: * Period 7: Dose Level 10 (Tablet) * Period 8: Dose Level 12 (Tablet) * Period 9: 12 mg (Capsule) * Period 10: Dose Level 11 (Tablet) * Period 11: Dose Level 13 (Tablet) * Period 12: Dose Level 16 (Tablet) * Period 13: 24 mg (Capsule) * Period 14: Dose Level 14 (Tablet) * Period 15: Dose Level 15 (Tablet) * Period 16: Dose Level 18 (Tablet) * Period 17: 36 mg (Capsule) * Period 18: Dose Level 17 (Tablet)

  • Experimental

    Part A: LY3502970 Oral Administration (Cohort 2A, Sequence 4)

    Participants received LY3502970 orally QD during home dosing Treatment Periods 1-6 (1 mg, 3 mg, and 6 mg; Capsule), followed by inpatient Treatment Periods 7-18 (7 days per period) and a follow-up visit approximately 7 days after the last dose. Doses during inpatient periods were administered as follows: * Period 7: Dose Level 12 (Tablet) * Period 8: Dose Level 10 (Tablet) * Period 9: Dose Level 11 (Tablet) * Period 10: 12 mg (Capsule) * Period 11: Dose Level 16 (Tablet) * Period 12: Dose Level 13 (Tablet) * Period 13: Dose Level 14 (Tablet) * Period 14: 24 mg (Capsule) * Period 15: Dose Level 18 (Tablet) * Period 16: Dose Level 15 (Tablet) * Period 17: Dose Level 17 (Tablet) * Period 18: 36 mg (Capsule)

  • Experimental

    Part B: LY3502970 Oral Administration (Cohort 1B, Sequence 1)

    Participants received LY3502970 orally QD across inpatient Treatment Periods 1-9 (7 days per period), followed by a follow-up visit approximately 7 days after the last dose. Doses were administered as follows: * Period 1: 1 mg (Capsule- First Treatment) * Period 2: 1 mg (Capsule- Second Treatment) * Period 3: 0.8 mg (Tablet) * Period 4: 3 mg (Capsule- First Treatment) * Period 5: 3 mg (Capsule- Second Treatment) * Period 6: 2.5 mg (Tablet) * Period 7: 6 mg (Capsule- First Treatment) * Period 8: 6 mg (Capsule- Second Treatment) * Period 9: 5.5 mg (Tablet)

  • Experimental

    Part B: LY3502970 Oral Administration (Cohort 1B, Sequence 2)

    Participants received LY3502970 orally QD across inpatient Treatment Periods 1-9 (7 days per period), followed by a follow-up visit approximately 7 days after the last dose. Doses were administered as follows: * Period 1: 1 mg (Capsule- First Treatment) * Period 2: 0.8 mg (Tablet) * Period 3: 1 mg (Capsule- Second Treatment) * Period 4: 3 mg (Capsule- First Treatment) * Period 5: 2.5 mg (Tablet) * Period 6: 3 mg (Capsule- Second Treatment) * Period 7: 6 mg (Capsule- First Treatment) * Period 8: 5.5 mg (Tablet) * Period 9: 6 mg (Capsule- Second Treatment)

  • Experimental

    Part B: LY3502970 Oral Administration (Cohort 1B, Sequence 3)

    Participants received LY3502970 orally QD across inpatient Treatment Periods 1-9 (7 days per period), followed by a follow-up visit approximately 7 days after the last dose. Doses were administered as follows: * Period 1: 0.8 mg (Tablet) * Period 2: 1 mg (Capsule- First Treatment) * Period 3: 1 mg (Capsule- Second Treatment) * Period 4: 2.5 mg (Tablet) * Period 5: 3 mg (Capsule- First Treatment) * Period 6: 3 mg (Capsule- Second Treatment) * Period 7: 5.5 mg (Tablet) * Period 8: 6 mg (Capsule- First Treatment) * Period 9: 6 mg (Capsule- Second Treatment)

  • Experimental

    Part B: LY3502970 Oral Administration (Cohort 2B, Sequence 1)

    Participants received LY3502970 orally QD during home dosing Treatment Periods 1-6 (1 mg, 3 mg, and 6 mg \[Capsule\]), followed by inpatient Treatment Periods 7-15 (7 days per period) and a follow-up visit approximately 7 days after the last dose. Doses during inpatient periods were administered as follows: * Period 7: 12 mg (Capsule- First Treatment) * Period 8: 12 mg (Capsule- Second Treatment) * Period 9: 9 mg (Tablet) * Period 10: 24 mg (Capsule- First Treatment) * Period 11: 24 mg (Capsule- Second Treatment) * Period 12: 14.5 mg (Tablet) * Period 13: 36 mg (Capsule- First Treatment) * Period 14: 36 mg (Capsule- Second Treatment) * Period 15: 17.2 mg (Tablet)

  • Experimental

    Part B: LY3502970 Oral Administration (Cohort 2B, Sequence 2)

    Participants received LY3502970 orally QD during home dosing Treatment Periods 1-6 (1 mg, 3 mg, and 6 mg \[Capsule\]), followed by inpatient Treatment Periods 7-15 (7 days per period) and a follow-up visit approximately 7 days after the last dose. Doses during inpatient periods were administered as follows: * Period 7: 12 mg (Capsule- First Treatment) * Period 8: 9 mg (Tablet) * Period 9: 12 mg (Capsule- Second Treatment) * Period 10: 24 mg (Capsule- First Treatment) * Period 11: 14.5 mg (Tablet) * Period 12: 24 mg (Capsule- Second Treatment) * Period 13: 36 mg (Capsule- First Treatment) * Period 14: 17.2 mg (Tablet) * Period 15: 36 mg (Capsule- Second Treatment)

  • Experimental

    Part B: LY3502970 Oral Administration (Cohort 2B, Sequence 3)

    Participants received LY3502970 orally QD during home dosing Treatment Periods 1-6 (1 mg, 3 mg, and 6 mg \[Capsule\]), followed by inpatient Treatment Periods 7-15 (7 days per period) and a follow-up visit approximately 7 days after the last dose. Doses during inpatient periods were administered as follows: * Period 7: 9 mg (Tablet) * Period 8: 12 mg (Capsule- First Treatment) * Period 9: 12 mg (Capsule- Second Treatment) * Period 10: 14.5 mg (Tablet) * Period 11: 24 mg (Capsule- First Treatment) * Period 12: 24 mg (Capsule- Second Treatment) * Period 13: 17.2 mg (Tablet) * Period 14: 36 mg (Capsule- First Treatment) * Period 15: 36 mg (Capsule- Second Treatment)

Primary outcomes2

Outcomes the sponsor listed as primary.

  1. Part B: Pharmacokinetics (PK): Steady-state Area Under the Concentration Time Curve From Time Zero to the End of the Dosing Interval, Tau (AUC[0-tau]) of LY3502970 on Day 7

    Time frame · Pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16 and 24 hours post-dose on Day 7 for each dosing treatment period (1 period=7 days)

    Registry description

    PK: Area under the concentration versus time curve from time 0 to the end of the once daily dosing interval at steady state AUC\[0-tau\] on Day 7.

  2. Part B: PK: Steady-state Maximum Observed Concentration (Cmax) of LY3502970 on Day 7

    Time frame · Pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16 and 24 hours post-dose on Day 7 for each dosing treatment period (1 period=7 days)

    Registry description

    PK: Maximum concentration of LY3502970 during a once daily dosing interval at steady state on Day 7.

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

Primary outcome results

Primary outcomeGeometric mean· Pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16 and 24 hours post-dose on Day 7 for each dosing treatment period (1 period=7 days)

Part B: Pharmacokinetics (PK): Steady-state Area Under the Concentration Time Curve From Time Zero to the End of the Dosing Interval, Tau (AUC[0-tau]) of LY3502970 on Day 7

GroupValue (Nanogram* hours/milliliter (ng*h/ml))Spread
Cohort 1B: 1 mg LY3502970 Capsule QD (First Treatment)80.237.8
Cohort 1B: 1 mg LY3502970 Capsule QD (Second Treatment)82.139.7
Cohort 1B: 0.8 mg LY3502970 Tablet QD78.936.6
Cohort 1B: 3 mg LY3502970 Capsule QD (First Treatment)24038.8
Cohort 1B: 3 mg LY3502970 Capsule QD (Second Treatment)25239.1
Cohort 1B: 2.5 mg LY3502970 Tablet QD24737.3
Cohort 1B: 6 mg LY3502970 Capsule QD (First Treatment)51747.4
Cohort 1B: 6 mg LY3502970 Capsule QD (Second Treatment)54160.4
Cohort 1B: 5.5 mg LY3502970 Tablet QD52445.4
Cohort 2B: 12 mg LY3502970 Capsule QD (First Treatment)82946.4
Cohort 2B: 12 mg LY3502970 Capsule QD (Second Treatment)84146.3
Cohort 2B: 9 mg LY3502970 Tablet QD79040.3
Cohort 2B: 24 mg LY3502970 Capsule QD (First Treatment)121050.0
Cohort 2B: 24 mg LY3502970 Capsule QD (Second Treatment)126057.5
Cohort 2B: 14.5 mg LY3502970 Tablet QD120064.2
Cohort 2B: 36 mg LY3502970 Capsule QD (First Treatment)150071.5
Cohort 2B: 36 mg LY3502970 Capsule QD (Second Treatment)150071.9
Cohort 2B: 17.2 mg LY3502970 Tablet QD152060.4
Primary outcomeGeometric mean· Pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16 and 24 hours post-dose on Day 7 for each dosing treatment period (1 period=7 days)

Part B: PK: Steady-state Maximum Observed Concentration (Cmax) of LY3502970 on Day 7

GroupValue (Nanogram per milliliter (ng/ml))Spread
Cohort 1B: 1 mg LY3502970 Capsule QD (First Treatment)5.3937.9
Cohort 1B: 1 mg LY3502970 Capsule QD (Second Treatment)5.6039.5
Cohort 1B: 0.8 mg LY3502970 Tablet QD5.3835.9
Cohort 1B: 3 mg LY3502970 Capsule QD (First Treatment)16.241.2
Cohort 1B: 3 mg LY3502970 Capsule QD (Second Treatment)16.838.8
Cohort 1B: 2.5 mg LY3502970 Tablet QD16.837.4
Cohort 1B: 6 mg LY3502970 Capsule QD (First Treatment)35.150.0
Cohort 1B: 6 mg LY3502970 Capsule QD (Second Treatment)36.863.6
Cohort 1B: 5.5 mg LY3502970 Tablet QD34.963.9
Cohort 2B: 12 mg LY3502970 Capsule QD (First Treatment)55.055.0
Cohort 2B: 12 mg LY3502970 Capsule QD (Second Treatment)55.651.3
Cohort 2B: 9 mg LY3502970 Tablet QD53.541.7
Cohort 2B: 24 mg LY3502970 Capsule QD (First Treatment)80.052.1
Cohort 2B: 24 mg LY3502970 Capsule QD (Second Treatment)82.660.6
Cohort 2B: 14.5 mg LY3502970 Tablet QD82.267.7
Cohort 2B: 36 mg LY3502970 Capsule QD (First Treatment)96.974.4
Cohort 2B: 36 mg LY3502970 Capsule QD (Second Treatment)96.275.8
Cohort 2B: 17.2 mg LY3502970 Tablet QD10565.2

Adverse events, as posted

Adverse events as posted: participants affected out of participants at risk, by group
GroupDeathsSerious eventsOther events
Cohort 1A: 1 mg LY3502970 Capsule QDParticipants who received 1 mg LY3502970 administered orally once daily as a capsule in Cohort 1A were included in this arm.0 / 520 / 526 / 52
Cohort 1A: LY3502970 Tablet QD (Dose Level 1)Participants who received LY3502970 (dose level 1) administered orally once daily as a tablet in Cohort 1A were included in this arm.0 / 520 / 528 / 52
Cohort 1A: LY3502970 Tablet QD (Dose Level 2)Participants who received LY3502970 (dose level 2) administered orally once daily as a tablet in Cohort 1A were included in this arm.0 / 520 / 527 / 52
Cohort 1A: LY3502970 Tablet QD (Dose Level 3)Participants who received LY3502970 (dose level 3) administered orally once daily as a tablet in Cohort 1A were included in this arm.0 / 520 / 529 / 52
Cohort 1A: 3 mg LY3502970 Capsule QDParticipants who received 3 mg LY3502970 administered orally once daily as a capsule in Cohort 1A were included in this arm.0 / 470 / 476 / 47
Cohort 1A: LY3502970 Tablet QD (Dose Level 4)Participants who received LY3502970 (dose level 4) administered orally once daily as a tablet in Cohort 1A were included in this arm.0 / 510 / 519 / 51
Cohort 1A: LY3502970 Tablet QD (Dose Level 5)Participants who received LY3502970 (dose level 5) administered orally once daily as a tablet in Cohort 1A were included in this arm.0 / 480 / 4810 / 48
Cohort 1A: LY3502970 Tablet QD (Dose Level 6)Participants who received LY3502970 (dose level 6) administered orally once daily as a tablet in Cohort 1A were included in this arm.0 / 510 / 5113 / 51
Cohort 1A: 6 mg LY3502970 Capsule QDParticipants who received 6 mg LY3502970 administered orally once daily as a capsule in Cohort 1A were included in this arm.0 / 460 / 467 / 46
Cohort 1A: LY3502970 Tablet QD (Dose Level 7)Participants who received LY3502970 (dose level 7) administered orally once daily as a tablet in Cohort 1A were included in this arm.0 / 460 / 466 / 46
Cohort 1A: LY3502970 Tablet QD (Dose Level 8)Participants who received LY3502970 (dose level 8) administered orally once daily as a tablet in Cohort 1A were included in this arm.0 / 470 / 477 / 47
Cohort 1A: LY3502970 Tablet QD (Dose Level 9)Participants who received LY3502970 (dose level 9) administered orally once daily as a tablet in Cohort 1A were included in this arm.0 / 460 / 4610 / 46
Cohort 2A: 1/3/6 mg LY3502970 Capsule QD (Home Dosing)Participants who received 1/3/6 mg LY3502970 administered orally once daily as a capsule in home dosing in Cohort 2A were included in this arm.0 / 520 / 5211 / 52
Cohort 2A: 12 mg LY3502970 Capsule QDParticipants who received 12 mg LY3502970 administered orally once daily as a capsule in Cohort 2A were included in this arm.0 / 500 / 507 / 50
Cohort 2A: LY3502970 Tablet QD (Dose Level 10)Participants who received LY3502970 (dose level 10) administered orally once daily as a tablet in Cohort 2A were included in this arm.0 / 500 / 5016 / 50
Cohort 2A:LY3502970 Tablet QD (Dose Level 11)Participants who received LY3502970 (dose level 11) administered orally once daily as a tablet in Cohort 2A were included in this arm.0 / 500 / 5011 / 50
Cohort 2A: LY3502970 Tablet QD (Dose Level 12)Participants who received LY3502970 (dose level 12) administered orally once daily as a tablet in Cohort 2A were included in this arm.0 / 500 / 508 / 50
Cohort 2A: 24 mg LY3502970 Capsule QDParticipants who received 24 mg LY3502970 administered orally once daily as a capsule in Cohort 2A were included in this arm.0 / 500 / 5013 / 50
Cohort 2A: LY3502970 Tablet QD (Dose Level 13)Participants who received LY3502970 (dose level 13) administered orally once daily as a tablet in Cohort 2A were included in this arm.0 / 491 / 4910 / 49
Cohort 2A: LY3502970 Tablet QD (Dose Level 14)Participants who received LY3502970 (dose level 14) administered orally once daily as a tablet in Cohort 2A were included in this arm.0 / 490 / 4913 / 49
Cohort 2A: LY3502970 Tablet QD (Dose Level 15)Participants who received LY3502970 (dose level 15) administered orally once daily as a tablet in Cohort 2A were included in this arm.0 / 500 / 5010 / 50
Cohort 2A: 36 mg LY3502970 Capsule QDParticipants who received 36 mg LY3502970 administered orally once daily as a capsule in Cohort 2A were included in this arm.0 / 450 / 459 / 45
Cohort 2A: LY3502970 Tablet QD (Dose Level 16)Participants who received LY3502970 (dose level 16) administered orally once daily as a tablet in Cohort 2A were included in this arm.0 / 450 / 459 / 45
Cohort 2A:LY3502970 Tablet QD (Dose Level 17)Participants who received LY3502970 (dose level 17) administered orally once daily as a tablet in Cohort 2A were included in this arm.0 / 450 / 459 / 45
Cohort 2A: LY3502970 Tablet QD (Dose Level 18)Participants who received LY3502970 (dose level 18) administered orally once daily as a tablet in Cohort 2A were included in this arm.0 / 450 / 459 / 45
Cohort 1B: 1 mg LY3502970 Capsule QDParticipants who received 1 mg LY3502970 administered orally once daily as a capsule in Cohort 1B were included in this arm.0 / 2150 / 21592 / 215
Cohort 1B: 0.8 mg LY3502970 Tablet QDParticipants who received 0.8 mg LY3502970 administered orally once daily as a tablet in Cohort 1B were included in this arm.0 / 2130 / 21349 / 213
Cohort 1B: 3 mg LY3502970 Capsule QDParticipants who received 3 mg LY3502970 administered orally once daily as a capsule in Cohort 1B were included in this arm.0 / 2100 / 21096 / 210
Cohort 1B: 2.5 mg LY3502970 Tablet QDParticipants who received 2.5 mg LY3502970 administered orally once daily as a tablet in Cohort 1B were included in this arm.0 / 2100 / 21057 / 210
Cohort 1B: 6 mg LY3502970 Capsule QDParticipants who received 6 mg LY3502970 administered orally once daily as a capsule in Cohort 1B were included in this arm.0 / 2031 / 20380 / 203
Cohort 1B:5.5 mg LY3502970 Tablet QDParticipants who received 5.5 mg LY3502970 administered orally once daily as a tablet in Cohort 1B were included in this arm.0 / 2031 / 20351 / 203
Cohort 2B:1/3/6 mg LY3502970 Capsule QD (Home Dosing)Participants who received 1/3/6 mg LY3502970 administered orally once daily as a capsule in home dosing in Cohort 2B were included in this arm.0 / 2130 / 213111 / 213
Cohort 2B:12 mg LY3502970 Capsule QDParticipants who received 12 mg LY3502970 administered orally once daily as a capsule in Cohort 2B were included in this arm.0 / 1860 / 18697 / 186
Cohort 2B:9 mg LY3502970 Tablet QDParticipants who received 9 mg LY3502970 administered orally once daily as a tablet in Cohort 2B were included in this arm.0 / 1860 / 18661 / 186
Cohort 2B:24 mg LY3502970 Capsule QDParticipants who received 24 mg LY3502970 administered orally once daily as a capsule in Cohort 2B were included in this arm.0 / 1810 / 18185 / 181
Cohort 2B:14.5 mg LY3502970 Tablet QDParticipants who received LY3502970 14.5 mg administered orally once daily as a tablet in Cohort 2B were included in this arm.0 / 1800 / 18056 / 180
Cohort 2B: 36 mg LY3502970 Capsule QDParticipants who received 36 mg LY3502970 administered orally once daily as a capsule in Cohort 2B were included in this arm.0 / 1761 / 17666 / 176
Cohort 2B: 17.2 mg LY3502970 Tablet QDParticipants who received 17.2 mg LY3502970 administered orally once daily as a tablet in Cohort 2B were included in this arm.0 / 1760 / 17635 / 176

Each cell reads participants affected / participants at risk, as the registry posted them.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies1

Studies that cite this trial.

Studies with results

1 study on this page

Indexing hint: Randomized controlled trial · 2026

3 results

Pharmacokinetic Bioequivalence of Orforglipron Tablets and Capsules in Healthy Participants With Obesity or Overweight.

Ma et al. 2026Diabetes, obesity & metabolismcited by 8

PMID 41994902PMC13243956DOI 10.1111/dom.70783PUB-41994902

Free to read · publisher termsCC BY-NC3 results
Read at sourceSee results (3)

Eligibility

Who could join, as posted.

Sex
All
Age
from 18 Years up to 65 Years
Healthy volunteers
Accepted
Inclusion and exclusion criteria, as posted
Inclusion Criteria: * Participants who are overtly healthy as determined by medical history and physical examination. * Have a stable body weight for one month prior to screening (less than or equal to 5 percent body weight gain or loss) and Body Mass Index (BMI) in range of 27 to 40 kilogram per meter square (kg/m²). * Participants must be reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures. * Have venous access sufficient to allow for blood sampling. Exclusion Criteria: * Have hemoglobin A1c (HbA1c) level of 6.5 percent (%) or greater. * Have a history of current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders or other significant active, uncontrolled medical conditions. * Have significant history of or currently have major depressive disorder or psychiatric disorder within the last 2 years. * Obesity induced by other endocrine disorders, such as Cushing's syndrome or Prader-Willi syndrome. * Have known clinically significant gastric emptying abnormality. * Have undergone bariatric surgery (for example: Lap-Band, Gastric Bypass) * Have a known self or family history (first-degree relative) of multiple endocrine neoplasia type 2A or type 2B, thyroid C-cell hyperplasia, or any form of thyroid cancer. * Have an abnormal 12-lead electrocardiogram (ECG) at screening. * Have history of pancreatitis. * Judged by the study investigator to be at serious suicidal risk and have answered "Yes" to either question 4 or 5 on the Columbia-Suicide Severity Rating Scale \[C-SSRS\]). * Have difficulty swallowing capsules or tablets.

PepBank is a research reference. Talk to a doctor before you use any peptide.